Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07486362 · ClinicalTrials.gov registry record
Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge
A clinical trial of Bacteremia, sponsored by Methodist Health System.
- Recruiting
- Registry status
- 126
- Enrollment target
- 1
- Study location
NCT07486362: Recruiting study of Bacteremia, sponsored by Methodist Health System.
NCT07486362 is a study of Bacteremia that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 126 participants, below the 7,565-participant average among 11 other Bacteremia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07486362, a study of Bacteremia, is actively recruiting participants, sponsored by Methodist Health System.
- RECRUITING
- Registry status
- 126 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients are commonly discharged from the Emergency Department(ED) with pending blood culture results. Blood cultures can take up to 48 hours to become positive which is why it is important to notify patients with true positive cultures as soon as possible. Delay in notification can lead to other serious complications such as sepsis, septic shock, and death. The American College of Emergency Physicians states pharmacists serve a critical role in ensuring efficient, safe, and effective medication use in the ED and advocates for health systems to support dedicated roles for pharmacists within the ED. Pharmacists help to decrease the workload on the healthcare team, especially in the ED where there is high volume and acuity.Emergency medicine pharmacist (EMP) play a significant role in the optimization of therapy, medication safety, and reducing costs. There is strong evidence for the positive impact EMPs have on microbiological culture review. Overall, pharmacist review of late cultures results in higher rates of appropriate antimicrobial therapy and decreased missed interventions.These prior studies focused on the review of microbiological tests, including sexually transmitted infections, urine, and wound cultures; however, there was limited data to support the role of pharmacists evaluating late blood culture results.
Primary Outcome
Time to patient notification is defined as time until the first attempt to contact the patient regarding the actionable positive res
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
Texas
- Clinical Research Institute Methodist Health System - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2028-01-31 |
What NCT07486362 shows while recruiting
NCT07486362 is an observational study that tracks outcomes without assigning an intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, below the 7,565-participant average among 11 other Bacteremia trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Bacteremia appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT07486362 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07486362 about?
NCT07486362 is a clinical study titled "Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge". Patients are commonly discharged from the Emergency Department(ED) with pending blood culture results. Blood cultures can take up to 48 hours to become positive which is why it is important to notify patients with true positive cultures as soon as possible. Delay in notification can lead to other se...
What is the current status of trial NCT07486362?
This trial is currently recruiting. The enrollment target is 126 participants. The study started on 2024-01-31. Estimated completion is 2028-01-31.
What conditions does trial NCT07486362 study?
This clinical trial studies the following conditions: Bacteremia.
What interventions are being tested in trial NCT07486362?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT07486362?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07486362 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacteremia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07486362's enrollment target sits among peer trials
126 10th of 11 higher than 2 of 11 other Bacteremia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bacteremia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reducing Risk for Infective Endocarditis
RECRUITING · NA
-
Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia
ACTIVE NOT RECRUITING
-
Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
COMPLETED
-
Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness
COMPLETED · NA
-
Multicenter Blood Culture Quality Improvement
COMPLETED · NA
-
Comparison of Infection Rates Among Patients Using Two Catheter Access Devices
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI